This Biotech CEO Is Using Neuroplastogenic Small-Molecule Therapeutics To Create Next Generation Mental Health. Dr Joseph Tucker – CEO Enveric $ENVB
Description
This Biotech CEO Is Using Neuroplastogenic Small-Molecule Therapeutics To Create Next Generation Mental Health. Dr Joseph Tucker – CEO Enveric $ENVB
Guest:
Dr. Joseph Tucker – CEO – Enveric Biosciences
Website:
https://www.enveric.com/
Company Bio:
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Dr. Tucker Bio:
Dr. Tucker is a seasoned executive who has built several publicly traded biotechnology companies. Dr. Tucker was a founder and Chief Executive Officer of Stem Cell Therapeutics, which he took public on the TSX (TSX: SSS). Trillium Therapeutics (NASDAQ: TRIL, TSX: TRIL) acquired Stem Cell Therapeutics in 2013. Dr. Tucker has also held the position of Co-Founder and Chief Executive Officer of Epimeron Inc., a University of Calgary start-up acquired in the creation of Willow Biosciences Inc. (TSX: WLLW). At Willow, Dr. Tucker served as Executive Chairman and Chief Operating Officer. Prior to founding companies, Dr. Tucker was a healthcare analyst with two investment banks and has also worked in technology commercialization for a university technology transfer office. Dr. Tucker received his Ph.D. in Biochemistry and Molecular Biology from the University of Calgary.
---
Support this podcast: https://podcasters.spotify.com/pod/show/smartmoneycircle/support
United States
